The LRATD1 (Leucine-Rich Repeat and Transmembrane Domain Containing 1) antibody is a tool used to study the LRATD1 protein, a relatively undercharacterized protein implicated in cellular processes such as membrane organization, intracellular signaling, and protein-protein interactions. LRATD1 contains leucine-rich repeats (LRRs), known for mediating molecular recognition, and a transmembrane domain, suggesting potential roles in cell surface or organelle membrane-associated functions. While its precise biological mechanisms remain unclear, LRATD1 has been linked to cancer progression, with studies reporting its overexpression in certain malignancies, including breast and lung cancers, where it may influence cell proliferation or survival pathways.
LRATD1 antibodies are typically produced in immunized hosts (e.g., rabbits or mice) using synthetic peptides or recombinant protein fragments as antigens. These antibodies enable researchers to detect LRATD1 expression in techniques like Western blotting, immunofluorescence, or immunohistochemistry. Validation often includes testing on cell lines with confirmed LRATD1 expression or knockout models to confirm specificity. Current research focuses on elucidating LRATD1's interaction networks, subcellular localization, and its potential as a diagnostic marker or therapeutic target. However, limited literature and functional data highlight the need for further investigation to fully define its role in health and disease.